Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
993.39
+6.12 (+0.62%)
Streaming Delayed Price
Updated: 2:39 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
36
37
Next >
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday
June 28, 2023
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%...
Via
Benzinga
Why Regeneron Stock Is Falling Today
June 27, 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of...
Via
Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
June 27, 2023
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday.
Via
Investor's Business Daily
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
June 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Regeneron Pharmaceuticals Stands With Analysts
June 27, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
June 22, 2023
Via
Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
June 09, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
June 07, 2023
Via
Benzinga
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
June 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
June 26, 2023
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks.
Via
Talk Markets
Biotech And Healthcare Stocks Lagging
June 21, 2023
Healthcare is a laggard with XLV down YTD but UNH is still a core position.
Via
Talk Markets
2 Biotech Stocks You Can Buy and Hold for the Next Decade
June 21, 2023
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.
Via
The Motley Fool
How to Retire Rich: Biotech Stocks Edition
June 18, 2023
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.
Via
InvestorPlace
Regeneron Pharmaceuticals Unusual Options Activity For June 05
June 05, 2023
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
May 30, 2023
Via
Benzinga
Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%
May 26, 2023
Via
Benzinga
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
June 14, 2023
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and
Via
Benzinga
2 Stocks to Buy No Matter What Happens in June and Beyond
June 14, 2023
A lot could go wrong in the next few months, but investors should largely ignore all that noise.
Via
The Motley Fool
3 Biotech Stocks to Sell in June Before They Crash and Burn
June 06, 2023
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them.
Via
InvestorPlace
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
June 05, 2023
Both of these stocks have declined over the past year.
Via
The Motley Fool
Regeneron Pharmaceuticals Unusual Options Activity For May 25
May 25, 2023
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
May 22, 2023
Via
Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
May 19, 2023
Via
Investor Brand Network
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
A Good Week For The Market But A Pause In The Biotech Rally
May 22, 2023
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.
Via
Talk Markets
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
May 22, 2023
Via
Benzinga
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
May 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 19, 2023
$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
36
37
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.